This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): abacavir, lamivudine and zidovudine
Description: Trizivir is a fixed-dose combination of Ziagen (Abacavir/ABC), Retrovir (Zidovudine/AZT), and Epivir (Lamivudine/3TC), three nucleoside reverse transcriptase inhibitors (NRTIs) already approved by FDA.
BioChem and GSK
Under the terms of the BioChem-Glaxo Wellcome license agreement signed in 1990, BioChem will receive a royalty based on sales and Glaxo Wellcome has the right to develop, manufacture and sell lamivudine worldwide subject to special arrangements in North America. An equally-owned Glaxo-BioChem joint venture will commercialize lamivudine in Canada. In the United States, Glaxo Wellcome will be responsible for seeking regulatory approval and commercializing lamivudine.
BioChem and Shire
In May 2001, the merger of Shire Pharmaceuticals Group with BioChem closed.
GSK & Pfizer
In April 2009, GlaxoSmithKline and Pfizer announced that the Companies have entered into an agreement to create a new HIV company (ViiV) focused solely on research, development and commercialisation of HIV medicines. Upon completion of the transaction, GSK will hold an 85% equity interest in the new company and Pfizer will hold 15% reflecting the value of their...See full deal structure in Biomedtracker
Partners: Pfizer Inc. Shire Pharmaceuticals Group PLC
Pink Sheet Call for GSK Trizivir withdrawal
Pink Sheet AIDS group seeks Trizivir withdrawal
Pink Sheet GSK Trizivir
Additional information available to subscribers only: